vs
KVH INDUSTRIES INC \DE\（KVHI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
KVH INDUSTRIES INC \DE\的季度营收约是REGENXBIO Inc.的1.0倍（$30.5M vs $30.3M），KVH INDUSTRIES INC \DE\净利率更高（1.1% vs -221.3%，领先222.4%），REGENXBIO Inc.同比增速更快（43.0% vs 13.4%），KVH INDUSTRIES INC \DE\自由现金流更多（$1.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.1%）
KVH工业公司是一家专注于惯性导航系统、卫星通信解决方案及运动传感产品研发、生产与销售的全球化科技企业，核心客户覆盖航空航天、国防、海事运输、自动驾驶等领域，业务遍及北美、欧洲及亚太地区。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
KVHI vs RGNX — 直观对比
营收规模更大
KVHI
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出29.6%
13.4%
净利率更高
KVHI
高出222.4%
-221.3%
自由现金流更多
KVHI
多$53.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
2.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.5M | $30.3M |
| 净利润 | $331.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -3.0% | -190.0% |
| 净利率 | 1.1% | -221.3% |
| 营收同比 | 13.4% | 43.0% |
| 净利润同比 | 107.7% | -31.2% |
| 每股收益（稀释后） | $0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KVHIRGNX
| Q4 25 | $30.5M | $30.3M | ||
| Q3 25 | $28.5M | $29.7M | ||
| Q2 25 | $26.6M | $21.4M | ||
| Q1 25 | $25.4M | $89.0M | ||
| Q4 24 | $26.9M | $21.2M | ||
| Q3 24 | $29.0M | $24.2M | ||
| Q2 24 | $28.7M | $22.3M | ||
| Q1 24 | $29.3M | $15.6M |
净利润KVHIRGNX
| Q4 25 | $331.0K | $-67.1M | ||
| Q3 25 | $-6.9M | $-61.9M | ||
| Q2 25 | $930.0K | $-70.9M | ||
| Q1 25 | $-1.7M | $6.1M | ||
| Q4 24 | $-4.3M | $-51.2M | ||
| Q3 24 | $-1.2M | $-59.6M | ||
| Q2 24 | $-2.4M | $-53.0M | ||
| Q1 24 | $-3.2M | $-63.3M |
毛利率KVHIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率KVHIRGNX
| Q4 25 | -3.0% | -190.0% | ||
| Q3 25 | -26.8% | -176.3% | ||
| Q2 25 | -1.4% | -296.3% | ||
| Q1 25 | -8.8% | 13.6% | ||
| Q4 24 | -11.9% | -242.1% | ||
| Q3 24 | -6.9% | -256.6% | ||
| Q2 24 | -10.1% | -251.3% | ||
| Q1 24 | -13.0% | -408.8% |
净利率KVHIRGNX
| Q4 25 | 1.1% | -221.3% | ||
| Q3 25 | -24.4% | -208.3% | ||
| Q2 25 | 3.5% | -331.8% | ||
| Q1 25 | -6.7% | 6.8% | ||
| Q4 24 | -16.0% | -241.3% | ||
| Q3 24 | -4.1% | -246.3% | ||
| Q2 24 | -8.3% | -237.7% | ||
| Q1 24 | -10.8% | -405.4% |
每股收益（稀释后）KVHIRGNX
| Q4 25 | $0.02 | $-1.30 | ||
| Q3 25 | $-0.36 | $-1.20 | ||
| Q2 25 | $0.05 | $-1.38 | ||
| Q1 25 | $-0.09 | $0.12 | ||
| Q4 24 | $-0.23 | $-0.99 | ||
| Q3 24 | $-0.06 | $-1.17 | ||
| Q2 24 | $-0.12 | $-1.05 | ||
| Q1 24 | $-0.16 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $69.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $131.0M | $102.7M |
| 总资产 | $151.5M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KVHIRGNX
| Q4 25 | $69.9M | $230.1M | ||
| Q3 25 | $72.8M | $274.2M | ||
| Q2 25 | $55.9M | $323.3M | ||
| Q1 25 | $48.6M | $267.9M | ||
| Q4 24 | $50.6M | $234.7M | ||
| Q3 24 | $49.8M | $255.5M | ||
| Q2 24 | $49.3M | $290.4M | ||
| Q1 24 | $66.6M | $338.7M |
股东权益KVHIRGNX
| Q4 25 | $131.0M | $102.7M | ||
| Q3 25 | $131.0M | $161.5M | ||
| Q2 25 | $138.4M | $213.7M | ||
| Q1 25 | $137.8M | $274.2M | ||
| Q4 24 | $138.6M | $259.7M | ||
| Q3 24 | $142.7M | $301.4M | ||
| Q2 24 | $143.4M | $348.3M | ||
| Q1 24 | $145.1M | $390.7M |
总资产KVHIRGNX
| Q4 25 | $151.5M | $453.0M | ||
| Q3 25 | $150.3M | $525.2M | ||
| Q2 25 | $152.0M | $581.0M | ||
| Q1 25 | $151.4M | $490.9M | ||
| Q4 24 | $155.1M | $466.0M | ||
| Q3 24 | $166.7M | $519.1M | ||
| Q2 24 | $168.9M | $569.4M | ||
| Q1 24 | $168.4M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $1.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 3.4% | -174.0% |
| 资本支出强度资本支出/营收 | 7.7% | 1.7% |
| 现金转化率经营现金流/净利润 | 10.25× | — |
| 过去12个月自由现金流最近4个季度 | $9.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流KVHIRGNX
| Q4 25 | $3.4M | $-52.3M | ||
| Q3 25 | $9.9M | $-56.0M | ||
| Q2 25 | $5.1M | $-49.3M | ||
| Q1 25 | $-1.3M | $33.6M | ||
| Q4 24 | $403.0K | $-31.6M | ||
| Q3 24 | $1.9M | $-40.5M | ||
| Q2 24 | $-14.7M | $-45.5M | ||
| Q1 24 | $-792.0K | $-55.5M |
自由现金流KVHIRGNX
| Q4 25 | $1.1M | $-52.8M | ||
| Q3 25 | $8.4M | $-56.5M | ||
| Q2 25 | $2.7M | $-49.7M | ||
| Q1 25 | $-2.4M | $32.6M | ||
| Q4 24 | $-444.0K | $-32.7M | ||
| Q3 24 | $419.0K | $-40.9M | ||
| Q2 24 | $-17.4M | $-46.0M | ||
| Q1 24 | $-3.2M | $-56.0M |
自由现金流率KVHIRGNX
| Q4 25 | 3.4% | -174.0% | ||
| Q3 25 | 29.5% | -189.9% | ||
| Q2 25 | 10.3% | -232.8% | ||
| Q1 25 | -9.5% | 36.6% | ||
| Q4 24 | -1.6% | -154.2% | ||
| Q3 24 | 1.4% | -168.9% | ||
| Q2 24 | -60.6% | -206.2% | ||
| Q1 24 | -10.9% | -358.5% |
资本支出强度KVHIRGNX
| Q4 25 | 7.7% | 1.7% | ||
| Q3 25 | 5.3% | 1.7% | ||
| Q2 25 | 8.8% | 1.8% | ||
| Q1 25 | 4.5% | 1.2% | ||
| Q4 24 | 3.1% | 5.1% | ||
| Q3 24 | 5.1% | 1.3% | ||
| Q2 24 | 9.4% | 2.1% | ||
| Q1 24 | 8.2% | 3.6% |
现金转化率KVHIRGNX
| Q4 25 | 10.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.48× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KVHI
| Services | $28.3M | 93% |
| Products | $2.2M | 7% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
